Alcami J, Joseph Munne J, Munoz-Fernandez M, Esteban M
Enferm Infecc Microbiol Clin. 2024; 23:15-24.
PMID: 38620211
PMC: 7130212.
DOI: 10.1016/S0213-005X(05)75157-0.
Zaunders J, Dyer W, Churchill M, Munier C, Cunningham P, Suzuki K
J Virus Erad. 2019; 5(2):73-83.
PMID: 31191910
PMC: 6543488.
Crowell T, Hatano H
J Virus Erad. 2016; 1(2):72-77.
PMID: 27123315
PMC: 4844069.
Yamada E, Yoshikawa R, Nakano Y, Misawa N, Koyanagi Y, Sato K
Viruses. 2015; 7(3):1373-90.
PMID: 25807049
PMC: 4379576.
DOI: 10.3390/v7031373.
Crowell T, Gebo K, Blankson J, Korthuis P, Yehia B, Rutstein R
J Infect Dis. 2014; 211(11):1692-702.
PMID: 25512624
PMC: 4447832.
DOI: 10.1093/infdis/jiu809.
Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.
Zou W, Denton P, Watkins R, Krisko J, Nochi T, Foster J
Retrovirology. 2012; 9:44.
PMID: 22640559
PMC: 3403983.
DOI: 10.1186/1742-4690-9-44.
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers.
Kamya P, Tsoukas C, Boulet S, Routy J, Thomas R, Cote P
AIDS Res Ther. 2011; 8(1):20.
PMID: 21679427
PMC: 3131237.
DOI: 10.1186/1742-6405-8-20.
Control of viral replication after cessation of HAART.
Van Gulck E, Heyndrickx L, Bracke L, Coppens S, Florence E, Buve A
AIDS Res Ther. 2011; 8(1):6.
PMID: 21314914
PMC: 3046910.
DOI: 10.1186/1742-6405-8-6.
HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals.
Raymond A, Campbell-Sims T, Khan M, Lang M, Huang M, Bond V
AIDS Res Hum Retroviruses. 2010; 27(2):167-78.
PMID: 20964480
PMC: 3064529.
DOI: 10.1089/aid.2009.0170.
Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progression.
Pushker R, Jacque J, Shields D
J Virol. 2010; 84(7):3644-53.
PMID: 20071583
PMC: 2838144.
DOI: 10.1128/JVI.01959-09.
Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.
Willer D, Guan Y, Luscher M, Li B, Pilon R, Fournier J
J Virol. 2009; 84(5):2304-17.
PMID: 20032177
PMC: 2820907.
DOI: 10.1128/JVI.01995-09.
T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors.
Sedaghat A, Rastegar D, OConnell K, Dinoso J, Wilke C, Blankson J
Clin Infect Dis. 2009; 49(11):1763-6.
PMID: 19857162
PMC: 2783537.
DOI: 10.1086/648081.
Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.
Nies-Kraske E, Schacker T, Condoluci D, Orenstein J, Brenchley J, Fox C
J Infect Dis. 2009; 199(11):1648-56.
PMID: 19432547
PMC: 4826569.
DOI: 10.1086/598980.
HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis.
Williams K, Burdo T
APMIS. 2009; 117(5-6):400-12.
PMID: 19400864
PMC: 2739573.
DOI: 10.1111/j.1600-0463.2009.02450.x.
Host genetic determinants of HIV pathogenesis: an immunologic perspective.
Hunt P, Carrington M
Curr Opin HIV AIDS. 2009; 3(3):342-8.
PMID: 19372988
PMC: 3475200.
DOI: 10.1097/COH.0b013e3282fbaa92.
HIV-1 Nef: at the crossroads.
Foster J, Garcia J
Retrovirology. 2008; 5:84.
PMID: 18808677
PMC: 2563024.
DOI: 10.1186/1742-4690-5-84.
Inefficient Nef-mediated downmodulation of CD3 and MHC-I correlates with loss of CD4+T cells in natural SIV infection.
Schindler M, Schmokel J, Specht A, Li H, Munch J, Khalid M
PLoS Pathog. 2008; 4(7):e1000107.
PMID: 18636106
PMC: 2444047.
DOI: 10.1371/journal.ppat.1000107.
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load.
Andrade A, Bailey J, Xu J, Philp F, Quinn T, Williams T
Clin Infect Dis. 2008; 46(8):e78-82.
PMID: 18444844
PMC: 2664682.
DOI: 10.1086/529387.
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K
J Infect Dis. 2008; 197(1):126-33.
PMID: 18171295
PMC: 3466592.
DOI: 10.1086/524143.
Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.
Rodriguez C, Koch S, Goodenow M, Sleasman J
Immunol Res. 2007; 40(3):271-86.
PMID: 17952387
DOI: 10.1007/s12026-007-0031-1.
